ONC vs. PFE: BeOne Medicines vs. Pfizer Stock Comparison

Company Profile

BeOne Medicines (ONC) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ONC is classified in Biotechnology while PFE is classified in Pharmaceuticals.

Pfizer (PFE) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Pfizer (PFE) is heavily traded at around 33.67M shares per day, whereas BeOne Medicines (ONC) sees a more moderate 405.29K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BeOne Medicines (ONC) at 18.40% sits in the top ROE quartile, while Pfizer (PFE) at 4.47% is closer to the peer norm — stronger capital efficiency for ONC.

For every dollar of sales, both BeOne Medicines (ONC) at 13.86% and Pfizer (PFE) at 6.34% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both BeOne Medicines (ONC) at 22.15% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

BeOne Medicines (ONC) at 40.23% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Pfizer (PFE) reports EPS growth of -3.55%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Pfizer (PFE) at 1.42 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for PFE.

BeOne Medicines (ONC) at 0.35 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; BeOne Medicines (ONC) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Pfizer (PFE) at 41.99 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while BeOne Medicines (ONC) at 7.04 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

Pfizer (PFE) at 1.88 is valued about in line with its industry on P/B ratio, while BeOne Medicines (ONC) at 7.98 carries an above-peer premium to book — ONC is pricier on assets.

Valuation Metrics